Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 880 is a predicted DNA-binding transcription factor belonging to the KRAB-type zinc finger protein family, characterized by the presence of C2H2 zinc finger domains and a KRAB domain. It functions in the regulation of gene transcription by RNA polymerase II and is active in the nucleus. ZNF880 has strong tissue-specific expression and participates in complex regulatory networks, including being regulated by miRNAs and lncRNAs. Reduced expression of ZNF880, through promoter hypermethylation and sequence variants, is strongly linked to worse outcomes (shorter overall and disease-free survival) in colorectal carcinoma. It also serves as a biomarker for distinguishing normal and tumor tissues in head and neck squamous cell carcinoma, with potential diagnostic utility supported by transcriptomic data. No drugs currently target ZNF880 directly, and therapeutic modulation of its expression (e.g., by targeting regulatory non-coding RNAs) remains experimental.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 880 (ZNF880).